Authors
Loading...
Randomized trial identifies PSMA4 as a causal target for atherosclerosis, suggesting new treatment options.
Yu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: